Skip to main content
. 2010 Aug 6;17(11):803–813. doi: 10.1038/cgt.2010.37

Figure 3.

Figure 3

(a) Sequential expression of hexon, E1A and GAPDH in TE-11 cells after Ad-delE1B55 infection (MOI=10). (b) Expression of hexon, E1A and GAPDH in TE-11 cells treated with three different schedules. Ad → 5-FU or VP-16, Ad-delE1B55 (MOI=10, day 1) followed by 5-FU (1.25 μ, day 2) or VP-16 (1.25 μ, day 2); 5-FU or VP-16 → Ad, 5-FU or VP-16 (day 1) followed by Ad-delE1B55 (day 2); Ad+5-FU or VP-16, Ad-delE1B55 plus 5-FU or VP-16 at the same time (day 1). The cells treated with the agent only or infected with the Ad only were also tested. Cell lysates were prepared 2 days after Ad-delE1B55 infection. (c) TE-1 or TE-11 cells were treated with Ad-delE1B55 (MOI=10) and/or 5-FU (10 μ) according to the schedule indicated in (b), and cell cycle was analyzed on day 4 (TE-1) or day 6 (TE-11). Respective cell populations showed the average of three samples. (d) Cytotoxic activity of the combination of Ad-delE1B55 (MOI=10) and anticancer agents (5-FU, 10 μ; MMC, 0.625 μ; VP-16, 2.5 μ; CDDP, 10 μ) to TE-1 cells with different treatment schedules. Asterisks show P<0.05.